Name: EXELIXIS INC (EXEL) Stock
Brand: EXELIXIS INC
Rating: 8.5 (3 reviews)

EXEL Latest News, Press Relases and Analysis

All

Press Releases

20 hours ago - By: Chartmill

EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity

3 days ago - By: Chartmill

Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock

5 days ago - By: Zacks Investment Research

Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention

9 days ago - By: Zacks Investment Research

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

11 days ago - By: Zacks Investment Research

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

15 days ago - By: Exelixis, Inc.

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

16 days ago - By: Zacks Investment Research - Mentions: AMGN MCD LITE

Company News for Nov 6, 2025

17 days ago - By: Zacks Investment Research - Mentions: ALKS FOLD

EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales

17 days ago - By: Zacks Investment Research

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

17 days ago - By: Zacks Investment Research - Mentions: BNGO

Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

17 days ago - By: Exelixis, Inc.

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

18 days ago - By: Benzinga - Mentions: KURA SEE HRMY FOLD ...

Earnings Scheduled For November 4, 2025

19 days ago - By: Benzinga

Preview: Exelixis's Earnings

24 days ago - By: Zacks Investment Research - Mentions: ADPT

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

a month ago - By: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

a month ago - By: Exelixis, Inc.

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

a month ago - By: Exelixis, Inc.

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

a month ago - By: Exelixis, Inc.

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

a month ago - By: The Motley Fool

The Ultimate Biotech Stock to Buy With $50 Right Now

2 months ago - By: The Motley Fool - Mentions: AXSM

EXELIXIS INC (EXEL) Stock News

EXEL Latest News, Press Relases and Analysis

EXELIXIS INC (NASDAQ:EXEL) Presents a Compelling Value Investment Opportunity

Exelixis Inc (NASDAQ:EXEL) Emerges as a Top Affordable Growth Stock

Why Exelixis (EXEL) International Revenue Trends Deserve Your Attention

Here's Why Exelixis (EXEL) is a Strong Momentum Stock

Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Company News for Nov 6, 2025

EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales

Exelixis (EXEL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Earnings Scheduled For November 4, 2025

Preview: Exelixis's Earnings

Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

The Ultimate Biotech Stock to Buy With $50 Right Now

Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years